ADMA Biologics Files 8-K for Disclosure
Ticker: ADMA · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, filing
Related Tickers: ADMA
TL;DR
ADMA Biologics filed an 8-K, standard disclosure update.
AI Summary
On October 9, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates ADMA Biologics is providing updates or disclosures to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not appear to contain any negative or significant new information.
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Registrant
- October 9, 2024 (date) — Date of earliest event reported
- 001-36728 (other) — Commission File Number
- 56-2590442 (other) — IRS Employer Identification No.
- 465 State Route 17, Ramsey, New Jersey 07446 (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing for ADMA Biologics, Inc.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported was on October 9, 2024.
What is ADMA Biologics, Inc.'s Commission File Number?
ADMA Biologics, Inc.'s Commission File Number is 001-36728.
Where are ADMA Biologics, Inc.'s principal executive offices located?
The principal executive offices are located at 465 State Route 17, Ramsey, New Jersey 07446.
Does this excerpt detail any specific financial results or new material events?
No, the provided excerpt does not detail specific financial figures or new material events.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-10-10 09:29:39
Filing Documents
- ef20037117_8k.htm (8-K) — 28KB
- 0001140361-24-043250.txt ( ) — 159KB
- adma-20241009.xsd (EX-101.SCH) — 4KB
- adma-20241009_lab.xml (EX-101.LAB) — 21KB
- adma-20241009_pre.xml (EX-101.PRE) — 16KB
- ef20037117_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. After market close on October 9, 2024, the management team of ADMA Biologics, Inc. (the "Company"), in speaking with its analysts regarding a change to the Company's auditors as described in the Company's Current Report on Form 8-K filed on October 9, 2024, stated that there is no anticipated impact to the Company's previously provided 2024-2025 financial guidance as a result of the auditor transition process.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADMA Biologics, Inc. October 10, 2024 By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President and Chief Executive Officer